RLMD (Relmada Therapeutics) Moat Score: 4/10 (As of Jun. 30, 2026)


RLMD Relmada Therapeutics Inc RLMD
29 GF Score
Price $6.92
! 3 Warning Signs
View Full Analysis

What is Relmada Therapeutics Moat Score?

Relmada Therapeutics RLMD -0.93% 29 Moat Score is 4 as of Jun. 30, 2026. GuruFocus rates RLMD with a GF Score™ of 29/100. The stock has 3 warning signs investors should review. Among 1,401 Biotechnology companies, Relmada Therapeutics ranks better than 88.79% on this metric.

Relmada Therapeutics has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Relmada Therapeutics has Narrow Moat: Relmada Therapeutics has a discernible moat due to its valuable intellectual property and consistent R&D capabilities. However, it lacks strong brand strength and significant customer switching costs.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Relmada Therapeutics might have Narrow Moat - Discernible but modest moat.

Relmada Therapeutics  (NAS:RLMD) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Relmada Therapeutics Moat Score Related Terms

RLMD vs ACRS, GYRE, SGP: Moat Score Comparison

For the Biotechnology subindustry, Relmada Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Relmada Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relmada Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Relmada Therapeutics's Moat Score falls into.


RLMD
29GF Score
Relmada Therapeutics Inc RLMD
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Relmada Therapeutics (RLMD) has a Moat Score of 4 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Relmada Therapeutics ranks #157 out of 1401 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Relmada Therapeutics' Moat Score too high?
Relmada Therapeutics' current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Relmada Therapeutics' value of 4 is 100% above this industry median. Based on the distribution chart, Relmada Therapeutics ranks #157 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Relmada Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Relmada Therapeutics' Moat Score compare to ACRS and GYRE?
According to the Biotechnology industry distribution chart, Relmada Therapeutics ranks #157 out of 1401 companies for Moat Score. This places Relmada Therapeutics in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Relmada Therapeutics' value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Relmada Therapeutics's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Relmada Therapeutics's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relmada Therapeutics stock overvalued right now?
Relmada Therapeutics (RLMD) has a current Moat Score of 4. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Relmada Therapeutics' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Relmada Therapeutics (RLMD), the current Moat Score is 4 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Relmada Therapeutics Business Description

Other Exchanges 4E2:Germany
Address 2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
29GF Score

Get the complete analysis for RLMD

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.92
Price